Study Phase 4

Evaluation of Efficacy and Safety of Long-acting Risperidone Microspheres in Patients With Schizophrenia or Schizoaffective Disorders, Who is Receiving Psychiatric Home-care Treatment, When Switching From Typical Depot or Oral Antipsychotics to Long-acting Risperidone Microspheres

Trial Information

Generic NameRisperidoneProduct NameRISPERDAL CONSTA®Therapeutic AreaNervous SystemProduct ClassPsycholepticsCondition StudiedSchizophreniaChemical SubgroupsN/APharmacological SubgroupsN/A
Sponsor Protocol NumberRISSCH4119 (RISC-TWN-MA10)Enrollment31Data PartnerJohnson & Johnson% Female35%Mean/Median Age (Years)37.6% WhiteN/A

Supporting Documentation

  • Clinical Study Report Available
Additional Information

Please note: individual participant-level data are not available for this trial. Only the clinical study report is available.

Approved Data Requests Associated with this Trial

Disclaimer

Clinical study data provided through this site do not replace the official labeling of a given drug product, which presents benefits and risks of the product for approved use(s). Before prescribing any product, health care professionals should consult the current prescribing information approved in their country. Patients seeking information may consult with their health care professional about the product, for which health authority approved written patient information may be available.